ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

MDV3100 Improves Survival, Reduces Death Risk by 37%

November 25, 2011

In Brief NCI-FDA Relations Tops, DeVita Says; Upon Talks to Candidates For Prospective Division

November 24, 1978

Government Shutdown Cancels NCI Site Visit To Mayo Cancer Center

October 11, 2013

Two Breast Cancer Screening Methods Found Equivalent

August 29, 2008

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

March 23, 2001

Guest Editorial : Why I Don’t Want to Pay for Your Horoscope: Reflections on FDA Warning to 23 and Me

December 13, 2013